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Abstract
Background: The purpose of this study was to evaluate the individualized and standardized quality
of life (QL) and psychological distress of patients participating in a Phase I trial of the novel
therapeutic reovirus (Reolysin).
Methods: 16 patients with incurable metastatic cancer were interviewed prior to being accepted
into the phase I trial with a semi-structured expectations interview, the Schedule for the Evaluation
of Individual Quality of Life – Direct Weighting (SEIQoL-DW), the European Organization for
Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), the Brief
Symptom Inventory (BSI), the Beck Depression Inventory (BDI), and the Spiritual Health Inventory
(SHI).
Results: Patients were able to complete all measures. They felt hopeful and excited about the trial,
with about two thirds hoping for disease regression and one third hoping for a cure. The most
commonly spontaneously nominated areas of QL were family relationships, activities and friends,
and the overall SEIQoL mean index score was 69. Health was nominated by only 38% of the sample.
Scores on the SEIQoL were correlated with global QL on the EORTC QLQ C-30. Scores on the
BDI and BSI were lower than reported for similar populations, and on the SHI scores were similar
to other samples. Global QL on the EORTC QLQ C-30 and depression scores were associated
with time to death in the nine patients who had died at the time of writing.
Conclusions: Individualized QL is easy to assess in seriously ill cancer patients, provides useful
information relative to each individual, and is related to standard QL measures. Repeated
assessment of individualized QL of patients in Phase I trials would be a useful addition to the
research.
Published: 27 January 2005
Health and Quality of Life Outcomes 2005, 3:7 doi:10.1186/1477-7525-3-7
Received: 26 October 2004
Accepted: 27 January 2005
This article is available from: http://www.hqlo.com/content/3/1/7
© 2005 Carlson et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Health and Quality of Life Outcomes 2005, 3:7 http://www.hqlo.com/content/3/1/7
Page 2 of 11
(page number not for citation purposes)
Background
As health care professionals begin to understand the
importance of quality of life (QL) and emotional and
social well-being in the treatment and progression of can-
cer, it has become standard practice, and in fact has been
described as a bioethical imperative, to include QL assess-
ment in all oncology clinical trials [1-7]. This is particu-
larly the case in Phase I trials for novel therapeutics, where
in many cases the patients admitted have exhausted other
treatment options and likely face death within months
under best supportive care [8]. A Phase I trial is the first
test of a new therapeutic in humans and aims to establish
a maximum tolerated dose, to evaluate dose limiting tox-
icity, and to examine the drug's pharmacology. There is
generally little chance of clinical disease response and rel-
atively high potential risk of toxicity in this type of trial.
For patients in this situation, quality of life remains per-
haps the most important variable to consider in the eval-
uation of the new treatment [9,10].
We report here on the initial QL of patients enrolled in the
Reolysin Phase I trial, the first clinical usage of the reovi-
rus in humans with cancer. The reovirus as a possible
treatment for cancer attracted a great deal of media atten-
tion when the journal Science, in 1998, published very
encouraging results showing tumor regression in animal
models [11]. Further work has established the reovirus as
a potential therapeutic in the treatment of brain, colorec-
tal, ovarian and breast cancer cell lines [12,13]. A small
sample of patients with different types of primary cancers
that had exhausted other treatment options, all of whom
had subcutaneous tumors that were easily palpable and
injectable with Reolysin, were enrolled in the current trial.
Due to the nature of the population under study, it
seemed especially important to use instrumentation that
was flexible enough to allow these very ill patients to iden-
tify what was important to each of them as individuals, as
well as to collect data from standardized instruments that
would allow direct comparisons with other patient popu-
lations. Thus, a battery of tests to measure both individu-
alized and standardized QL, distress levels, and
spirituality was selected. Important aspects of QL were
measured, including physical, psychological, emotional,
social, and spiritual functioning, with emphasis on mood
states and psychopathology. Expectations and hopes
regarding participation in the trial were also elicited dur-
ing a semi-structured interview.
The specific instruments used included an interview-
based subjective measure of QL, the Schedule for the Eval-
uation of Individual Quality of Life – Direct Weighting
(SEIQoL – DW)[14]. The SEIQoL-DW is a relatively new
measure and unique in QL measurement in that it elicits
from patients their own self-generated list of the "five
most important domains of QL" for them, rather than
asking about pre-set areas. After patients identify their
most important domains, they rate how well each domain
is for them currently, and how important overall in their
lives each domain is. This instrument and its predecessor,
the SEIQoL [15], have been used in oncology in several
published studies [16-18]. The SEIQoL differs from the
SEIQoL-DW in that a procedure called judgement analysis
is used in the SEIQoL to arrive at the relative importance
of each of the domains for each patient. This process is
much more time consuming, abstract and complicated
than the direct weighting procedure used in the SEIQoL-
DW. While the SEIQoL procedure has been deemed overly
burdensome for some patients with both early and
advanced cancer [16,17], primarily due to the judgement
analysis portion of the procedure, the SEIQoL-DW has
been found to be acceptable and practical to use in a vali-
dation study of patients on Phase I clinical trials [18].
Another study of the SEIQoL-DW found that patients with
advanced cancer were good judges of their own QL, and
able to complete the interview with little difficulty [17].
In past studies, the most important areas of QL that
patients on Phase I clinical trials identified were equally
health and family [18]. However, in a sample of advanced
cancer patients family concerns were consistently identi-
fied as more important than health issues [17]. The
patient population in the Campbell & White study [18]
was not defined except by their participation in Phase I tri-
als, whereas the Waldron & O'Boyle sample [17] all had
advanced incurable cancer. It may be the case that as ill-
ness severity progresses, concerns are directed toward
domains that offer more hope. Other studies that have
used the SEIQoL found family, health and finances to be
the top three areas in men with early stage prostate cancer
[16], and similarly family, health, marriage and leisure/
hobbies were most important to a group of cardiac
patients [19]. Thus, although there does seem to be some
consistency in the areas nominated by diverse patient
groups, differences in the relative importance of the areas
are commonly found.
The other QL questionnaire used in this study is the very
widely used European Organization of Research and
Treatment of Cancer (EORTC) Quality of life Question-
naire (QLQ C-30), a 30 item standardized self-adminis-
tered questionnaire that taps into important domains of
QL, including physical, psychological, emotional and
social functioning. This was included to allow compari-
sons with a well-known and validated standardized qual-
ity of life questionnaire with set domains and subscale
scores. Another study at our Centre directly compared the
SEIQoL to the EORTC QLQ C-30 in a sample of early stage
prostate cancer patients [16]. The authors compared the
domains nominated by the patients to those included onHealth and Quality of Life Outcomes 2005, 3:7 http://www.hqlo.com/content/3/1/7
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the EORTC QLQ C-30, and concluded that although there
was substantial overlap on some items, many items iden-
tified by patients were not included on the standardized
questionnaire.
The area of spirituality was also of interest in this popula-
tion of very ill people, as issues of death and dying are
often accompanied by questioning in the realm of spirit-
uality. The Spiritual Health Inventory [20] was used for
this purpose, as it measures self-acceptance, relationships
with others, and hope, which may be an important factor
as patients participate in the trial. In terms of depression,
anxiety and other psychiatric symptoms that are frequent
in cancer patients, the Brief Symptom Inventory (BSI)[21]
was used to broadly assess many areas of psychopathol-
ogy, and the Beck Depression Inventory (BDI)[22] to
focus in more detail on depressive symptomatology. Both
of these instruments are widely used in the oncology liter-
ature and thus there are many published reports with val-
ues that can be used for comparison purposes.
Previous work with patients in Phase I trials has found
that patients' expectations going into trials are generally
more optimistic than oncologists'. Patients with incurable
malignancy in a Phase I trial estimated a greater potential
for benefit from the experimental therapy than did oncol-
ogists [10]. They also estimated that the experimental
therapy had less potential for toxicity than the standard
treatment. The oncologists estimated the potential for tox-
icity on both treatments to be about equal, and lower,
than did patients. Patients in Phase I trials for new drugs,
when asked why they had agreed to try the new treatment,
cited the potential for helping their disease to be the
number one reason for participation [9]. Indeed, despite
cautious words from the medical staff, it is not surprising
that patients with a disease resistant to all other treat-
ments might hope for at least a slowing of their disease
progression with an experimental treatment. Thus, the
preliminary QL of such patients, as measured in the cur-
rent study, may be inflated by these hopes. Other studies
looking at the effects of participation in Phase I trials on
QL have found either no detrimental effects of participa-
tion [8], or enhancement of QL over the course of the trial
compared to a control group that received supportive care
[23].
The purpose of the current study was to investigate indi-
vidualized QL in a group of patients with metastatic incur-
able cancer participating in a Phase I trial of a highly
media lauded new therapeutic, and investigate their
expectations regarding the trial. Areas of importance and
SEIQoL Index scores for these patients will be compared
with those of patients in other studies, and compared to
their own scores on the standardized QL and psychologi-
cal measures assessed. Relationships between the different
measures will also be explored.
Methods
Subjects
Patients were recruited as specified in the protocol: "A
Phase I Clinical Trial to Evaluate Dose Limiting Toxicity
and Maximum Tolerated Dose of Intralesional Adminis-
tration of REOLYSIN for the Treatment of Histologically
Confirmed Malignancies". All patients had histologically
confirmed evaluable palpable tumors of any histological
type that had failed to improve on existing standard ther-
apy. The injectable lesion was required to be between 1
and 10 cm2, and accessible and measurable for delivery of
an intralesional injection. Patients were required to have
a life expectancy of at least 12 weeks and a ECOG perform-
ance status of ≤ 3 and must not have received active cancer
treatment for least 21 days prior to entrance onto the trial.
Adequate organ reserve in terms of bone marrow, hepatic,
renal and cardiac functions was required. Patients on
immunosuppressive therapy or alternative/complimen-
tary/unproven systemic or local therapies were ineligible.
Procedures
After patients had been referred to the above mentioned
trial, but prior to being definitively accepted (pending
complete assessment of inclusion/exclusion criteria),
patients met with a psychologist (LC) for the assessment
protocol. At that time they were interviewed concerning
their expectations about their health, both without any
further conventional treatment and with the potential
experimental treatment. They then completed the inter-
view-based individualized QL interview, followed by the
quantitative questionnaires as detailed below. All 16
patients followed the same procedures.
Instruments
Demographics Form
Demographic information including age, education, mar-
ital status, occupation and current employment status was
obtained on a form created for this study. Medical history
including type of illness, dates of first diagnosis and sub-
sequent relapses and site of metastases were collected, and
later verified from patient charts.
Expectations Interview
Patients were asked three questions in a semi-structured
interview: How do you feel about potentially being a part
of this trial? How do you see your disease progressing
without any further conventional treatment? Once on the
trial, how do you see your disease progressing? Short
answers to these questions were recorded verbatim at the
time of the interview.Health and Quality of Life Outcomes 2005, 3:7 http://www.hqlo.com/content/3/1/7
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Quality of Life
Schedule for the Evaluation of Individual Quality of Life – Direct 
Weighting (SEIQoL – DW) [14]
This schedule takes the form of a semi-structured inter-
view, in which the investigator first describes quality of
life as an individually defined construct, then elicits from
the patient their own five most important domains of QL,
rather than asking them about pre-set areas. Patients are
asked to think of what areas of life determine their own
happiness, or quality of life. After patients identify their
most important domains ("cues"), they rate the quality of
each domain currently in their lives by drawing a bar
graph on a 100 mm scale from worst possible to best pos-
sible. This is called the "level" of the cue. Finally, they rate
how important each domain is overall in their lives using
a direct weighting disk. This disk consists of five overlap-
ping different colored laminated disks that can be rotated
around a central point to form a pie chart. Each piece rep-
resents one of the five chosen domains. The patient
manipulates the disk until the proportion of each piece
making up the pie represents the relative importance of
that domain in their lives ("weight"). The weight value of
each cue is calculated by determining the percentage of
the overall pie that each piece covers by reading off a
larger backing disk that is labeled with a 0–100 scale
around the pie. Then by multiplying the level of each
domain by its weight and summing the product for all five
items, a summary score representing overall subjective
quality of life can be calculated. This is called the SEIQoL
Index Score. More detailed descriptions of the procedures
are available in other publications [14,18,24].
The European Organization for Research and Treatment of Cancer 
(EORTC) QLQ-C30 Quality of Life Questionnaire [25]
This 30-item questionnaire includes five functional
domains of quality of life: physical function (5 items),
emotional function (4 items), cognitive function (2
items), social function (2 items) and role function (2
items). There are also several symptom scales: fatigue (3
items), pain (2 items), nausea and vomiting (2 items),
and one item each for dyspnea, sleep disturbance, appe-
tite, constipation, diarrhea and financial difficulties.
Finally, two items assess global quality of life. The ques-
tionnaire shows high internal consistency, and overall
reliability and validity of the survey has been demon-
strated in international clinical trials with cancer patients
of heterogeneous diagnoses including lung cancer [26].
Distress
Beck Depression Inventory (BDI) [22]
This 21-item questionnaire gives a global score on depres-
sive symptoms, and norms are available for many differ-
ent populations, including cancer patients. Higher scores
represent more depressive symptoms.
Brief Symptom Inventory (BSI) [21]
A general mental health measure of 58 questions which
provides scores on nine dimensions of psychopathology
or psychological distress: somatization, obsessive-com-
pulsive, interpersonal sensitivity, depression, anxiety,
hostility, phobic anxiety, paranoid ideation, and psy-
choticism. Three global scores can be calculated: the Glo-
bal Severity Index (GSI), the Positive Symptom Total
(PST) and the Positive Symptom Distress Index (PSDI).
The GSI was used as the global score in this study.
Spirituality
Spiritual Health Inventory (SHI) [20]
This instruments defines spiritual health as the capacity to
transcend oneself and meet three basic needs; the need for
self-acceptance, the need for relationships with others
and/or a supreme being, and the need for hope. These
three factors accounted for 71% of the variance in validity
studies. A single total score is calculated by summing all
items. The possible range of scores is 31–155, with higher
scores indicating higher levels of spiritual health. The 31-
item questionnaire takes very little time to complete.
Results
Subjects
Demographic characteristics and disease variables of par-
ticipants are presented in Table 1. Patient #10 was regis-
tered in the trial but too ill to complete any of the
questionnaires or the interview. Therefore no data for this
patient is included in the study. The remaining 16 patients
who provided data all had metastatic disease that was
considered incurable, 6 men and 10 women. The largest
patient group consisted of five women who had meta-
static breast cancer, followed by three patients with malig-
nant melanoma. Patients ranged in age from 32 to almost
76 years old, with a median age of 53 years. They had been
diagnosed with cancer for a median of 3.3 years (range
0.5–26.9 years) before entrance to the study. They had on
average 16 years of education (range 12–25), and there-
fore represented a highly educated group. At the time of
analysis, nine of the patients had died, at a median of 136
days from the time of the interview (range 21–664 days).
The remaining seven were still alive, a median of 242 days
from the time of the interview (range 207–709 days).
Expectations Interview
Interviews were conducted with all of the 16 patients. To
the question "How do you see your disease progressing
without further conventional treatment?", nine of the
patients indicated they felt it would get worse and they
would eventually die of their disease. This was stated in
different ways: Nothing else left...getting gradually
worse...terminal – could be months, could be
years...wouldn't go very well. The other seven patients
offered more hopeful or neutral prognoses: don't thinkHealth and Quality of Life Outcomes 2005, 3:7 http://www.hqlo.com/content/3/1/7
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about it – stay positive...still hopeful and optimis-
tic...other things available still...would still take chemo,
hope it would work...wouldn't ever give up on
hope...faith...not sure, unknown. When asked how they
felt about being in the trial, most patients indicated feel-
ing excited, fortunate, grateful and hopeful. One indicated
that they felt scared as well as hopeful, not knowing what
to expect, and one said they felt like a guinea pig. To the
question "Once on the trial, how do you see your disease
progressing?", ten of the patients mentioned hoping for
the tumor to shrink, for a remission, or for some exten-
sion of life. Five patients mentioned hoping for a cure, to
be cancer free. One patient just mentioned hoping to help
others, and four others said that although they were hop-
ing for personal benefit, if it didn't help them it might
help others in the future. In general, patients were hopeful
yet philosophical about the trial. The 54-year old woman
with melanoma captured these sentiments with her com-
ments: It feels hopeful. Maybe it won't help me – I won't
be disappointed. It might help others down the road. It's
on the frontier – exciting. If it works it's a bonus. I don't
totally expect anything. It may extend life. Just day by day
carry on.
Table 1: Demographic and Disease Characteristics
Patient 
Number
Gender Age 
(Years)
Cancer diagnosis Years 
since first 
diagnosis
Location of metastases Days from 
interview to 
death
1 Female 45 Mucoepidermoid carcinoma (head and neck) 14.7 Lymph nodes 28
2 Male 50 Squamous carcinoma (head and neck) 0.7 Lymph nodes Alive-709
3 Female 54 Anaplastic thyroid carconoma 10.8 Lungs/liver/bone 21
4 Female 47 Malignant Melanoma 12.7 Eye/breast/liver/chest wall/lung 664
5 Female 47 Metastatic Breast carcinoma 6.6 Chest wall/bone 241
6 Female 60 Metastatic Breast carcinoma 2.7 Chest wall /lungs /retroperitoneum Alive-529
7 Male 32 Soft tissue sarcoma 0.5 Right lower extremity 96
8 Male 56 Neuroendocrine islet cell tumor 2.4 Liver/face/neck/ Scalp 44
9 Female 56 Metastatic Breast carcinoma 2.7 Chest wall/ left supraclavicular skin/ 
intrabdomen
142
11 Male 42 Malignant melanoma 6.4 Liver/lung/spleen Alive-368
12 Male 64 Klatskin's tumor 1.4 Abdomen 171
13 Female 76 Metastatic Breast carcinoma 26.9 Lung/bone/liver 136
14 Female 55 Malignant melanoma 1.8 Axilla /lung /liver Alive-242
15 Female 48 Metastatic breast carcinoma 2.8 Neck /Chest Wall /Brain Alive-242
16 Female 46 Soft tissue sarcoma 3.9 Lung/skin/breast/ retroperitoneal Alive-227
17 Male 70 Squamous carcinoma (head and neck) 9.7 Head/neck Alive-207
Table 2: EORTC Scores
Functional Scales (Higher scores = higher function) Mean SD
Physical Function 63.75 32.02
Role Function 62.50 38.73
Emotional Function 75.52 18.12
Cognitive Function 76.04 24.32
Social Function 55.21 32.04
Global Quality of Life 57.22 21.79
Symptom Scales (Higher scores = more symptomatic)
Fatigue 41.67 25.82
Nausea 14.58 14.75
Pain 41.67 25.82
Dyspnea 22.92 26.44
Sleep 35.42 30.96
Appetite 33.33 32.20
Constipation 25.00 28.55
Diarrhea 14.58 17.78
Finances 29.17 26.87
Table 3: Psychological Scores
Mean SD
BSI Somatization 0.74 0.56
BSI Obsessive Compulsive 0.91 0.63
BSI Interpersonal Sensitivity 0.38 0.36
BSI Depression 0.76 0.62
BSI Anxiety 0.50 0.40
BSI Hostility 0.21 0.27
BSI Paranoid Ideation 0.17 0.17
BSI Psychoticism 0.16 0.17
BSI Global Severity Index 0.55 0.36
Beck Depression Inventory Total Score 11.40 9.46
Spiritual Health Inventory Total Score 118.33 16.02Health and Quality of Life Outcomes 2005, 3:7 http://www.hqlo.com/content/3/1/7
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EORTC QLQ C-30
Quality of life scores on the EORTC QLQ C-30 are pre-
sented in Table 2. All 16 patients completed the question-
naire. On the functional scales, where higher scores
indicated better functioning, scores ranged from a low of
55 on social functioning, to a high of 76 for cognitive
functioning, on a scale of 1–100. The overall global QL
rating was 57. On the symptom scales, where higher
scores indicate more symptomatology, scores ranged from
a low of 14 (nausea and diarrhea) to a high of 42 on pain
and fatigue. The next most prevalent symptoms were sleep
problems and appetite loss.
Correlations between subscales are presented in Table 6
(additional file 1). The subscales of role function, cogni-
tive function, global QL, fatigue and appetite loss were sig-
nificantly related to seven other subscales each. Social
functioning was associated with scores on six other sub-
scales. Finances, diarrhea, and sleep were unassociated
with any other subscales, and pain was associated only
with dyspnea. All significant correlations were in the
expected directions.
Psychological Scores
Scores on the BDI, BSI and SHI are presented in Table 3.
Fifteen of the 16 patients completed the questionnaires.
Scores on the BDI averaged 11, in the moderate range of
depressive symptomatology. On the BSI, scores ranged
from a low of 0.17 on paranoid ideation, to a high of 0.91
on the obsessive-compulsive subscale. The overall global
severity index was 0.55. These scores are higher than those
of the general population, but quite a bit lower than those
of psychiatric outpatients [21].
Patients scored an average of 118 on the SHI. The most
highly endorsed items on the scale of 1–5, where 1 corre-
sponds with the heading "not at all", and 5 with "very
much", were the following: "I believe other people accept
me even with my faults" (4.5); "I actively participate in
decisions concerning my health care" (4.5); "I believe my
nurses and doctors care about me" (4.3); "My life has a
purpose" (4.2); "I feel accepted and forgiven despite some
past actions" (4.0). The lowest scores were on the follow-
ing items: "I wonder if God is angry with me" (1.1); "I feel
angry with others" (1.3); "I feel a need to be forgiven for
some of my thoughts and feelings" (1.7); "I worry about
life after death" (1.9); "I feel angry with myself" (1.9); and
"I feel out of touch with my own feelings and with others"
(1.9).
SEIQoL
All 16 patients completed the SEIQoL. The average time
taken was 13.5 minutes, range 5–30 minutes. Areas iden-
tified by patients as the most important in determining
their overall quality of life are presented in Table 4 by
patient, along with average levels and weights associated
with each cue by order of identification. As can bee seen,
most patients identified family, children, or spouse as the
single most important factor in determining their current
quality of life. The average level of each of the five cues
Table 4: SEIQoL Items
Patient Number Item 1 Item 2 Item 3 Item 4 Item 5
1 Children Spouse Religion Physical Fitness Finances
2 Family Exercise Nature Computer Work
3 Spouse Children Friends Activities Father
4 Family Friends Dog Gardening Fun
5 Pain Control Finances Health Energy Activities
6 Travel Health Family and Friends Spouse Activities
7 Children Family Mobility Hope Work
8 Work Family Finances Health Activities
9 Family Grandchildren Friends Travel with Spouse Finances
11 Family Friends Active at Home Work Finances
12 Spouse Friends Family Belief Art
13 Activity Grandchildren Sewing Gardening Travel
14 Family Faith Positivity Activities Friends
15 Work Recreation Mobility Family Friends
16 Spouse Children Family Faith Exercise
17 Family Spouse Work Family tree Religion
M e a n  L e v e l 7 0 . 96 8 . 46 4 . 65 6 . 96 2 . 5
SD 31.3 26.0 32.0 32.1 27.1
Mean Weight 0.25 0.23 0.19 0.20 0.16
SD 0.08 0.08 0.06 0.08 0.09Health and Quality of Life Outcomes 2005, 3:7 http://www.hqlo.com/content/3/1/7
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ranged from 57–71 on a scale of 0–100, where 100 was
the best possible state for that cue. The weights assigned to
the cues varied from 16% to 25%, a fairly narrow range,
with those cues identified earlier in the process generally
being assigned higher importance. The overall index
scores, which take into account both the level of the cue
and its weight, were an average of 69, SD 20.5 and ranged
from 27–100. The frequency of nomination of different
cues as any of the five domains is presented in Table 5. All
but one patient mentioned some family relationship as
one of the five domains, while some patients nominated
several different specific family relationships. This was fol-
lowed by the general ability to participate in chosen activ-
ities (e.g. exercise, recreation, travel, gardening, sewing).
Seventy-five percent of the patients nominated some type
of activity in their top five. The next most frequent cate-
gory was friends, endorsed by 44% of the patients. This
was followed equally by health (mobility, fitness, energy),
faith (religion, belief, hope), and work, with 38% of the
patients nominating each category. Finances were nomi-
nated by 31% of the patients, followed by several items
that were mentioned by only one person each and war-
ranted separate categories.
The internal validity of each of the cues was assessed by
performing regressions of the combination of each cue
level and its weight onto the total index scores. The result-
ing R2 values ranged from .19–.76, median .47, mean .50.
The highest R2 value was for the first cue generated, and
the lowest value was associated with the fourth cue. This
is much lower than in previous reports [16,17] and may
constitute reason to pause before attributing high levels of
credence to the validity of all of the cues in influencing
overall QL.
Two examples of cues, cue levels and cue weights are illus-
trated in Figures 1 and 2. Figure 1 illustrates the responses
of patient #1, a 45 year old woman with mucoepidermoid
cancer of her head and neck region who died four weeks
following the interview. The most important areas to her
were health, followed by children, spouse, religion and
finally finances. This profile is unusual for this group in
that most patients, if they nominated health as a cue at all,
did so later in the process. She indicated that the areas that
were going the best were finances and religion, followed
by children, spouse and health. This combination of
things not rated as going very well in some important
areas resulted in an index score of 59 on the SEIQoL This
is quite a bit higher than her global QL score on the
EORTC of just 25. Another example is patient #2 (figure
2), a 50 year-old male with head and neck cancer who, as
of this writing, has been alive for 709 days following the
interview. For him, things were going well in the areas
most important to him; family, work and computers. This
resulted in an index score of 81, consistent with his global
QL score on the EORTC of 75. These examples illustrate
that the SEIQoL scores are related to overall QL scores,
and suggest that they may be related to health status as
well.
Correlations between measures
Correlations between the SEIQoL index and scores on the
other measures are presented in Table 6 (see additional
file 1 – Carlson Table 6.doc). The index score was signifi-
cantly positively correlated with the global QL score (r =
.53, p < .05), and negatively associated with the symptoms
of nausea (r = -.58, p < .05), pain (r = -.53, p < .05) and
appetite loss (r = -.59, p < .05) on the EORTC QLQ C-30.
Scores on the BDI were positively associated with appetite
loss (r = 0.56, p < .05) and fatigue (r = 0.56, p < .05), not
surprising since these are both symptoms of depression
assessed by the BDI. Depression scores were also nega-
tively related to social functioning (r = -.79, p < .01) and
global quality of life (r = -.69, p < .01), indicating that peo-
ple who endorsed more depressive symptoms also tended
to report lower social functioning and lower overall QL.
Higher scores on the Global Severity Index of the BSI were
associated with worse emotional (r = -.55, p < .05), cogni-
tive (r = -.58, p < .05) and social (r = -.69, p < .01) func-
tioning, as well as worse global QL (r = -.70, p < .01) and
more sleep disturbance on the EORTC. Higher scores on
the spiritual health inventory were associated with lower
scores on the global severity index of the GSI (r = -.54, p <
.05) and less nausea (r = -.63, p < .05).
Significant correlations between days to death and psy-
chological scores were found on two instruments in the
Table 5: Frequency of Cue Nomination
Cue N (out 
of 16)
%
Family (Children, Spouse, Grandchildren, Parent, 
Family Tree)
15 93.8
Activities (exercise, gardening, sewing, 
recreation, travel)
12 75
Friends 7 43.8
Health (mobility, physical fitness, energy) 6 37.5
Faith (religion, belief, hope) 6 37.5
Work 6 37.5
Finances 5 31.3
Pet 1 6.3
Computer 1 6.3
Pain Control 1 6.3
Art 1 6.3
Fun 1 6.3
Positivity 1 6.3
Nature 1 6.3Health and Quality of Life Outcomes 2005, 3:7 http://www.hqlo.com/content/3/1/7
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nine patients who had passed away at the time of writing.
The BDI total score was negatively correlated (r = -.75, p <
.05), and the EORTC global QL score was positively corre-
lated (r = .77, p < .05) with time to death. This indicates
an association between higher levels of depression and
lower global QL at the time of the interview, and fewer
days to death.
Discussion
This study is the first to use the SEIQoL-DW instrument to
assess individualized QL in a population of patients with
advanced cancer participating in a Phase I clinical trial. Of
note is that the instrument was easy to use in this popula-
tion and acceptable even to those patients who were quite
ill. Replication of the wide range of individual differences
in the cues chosen and the weights associated with each
cue was seen in this group. The areas of QL that were
nominated by patients as the most important factors in
the determination of their overall QL were primarily fam-
ily relationships, the ability to participate in pleasurable
activities, and friendships. Only 38% of this sample men-
tioned health or health-related domains such as mobility,
fitness and energy as one of the five cues. This is in con-
trast to other samples of cancer patients where over 70%
of patients nominated health as an important domain.
For example, health was nominated by 73% of cancer
patients in phase I trials (not necessarily advanced cancer)
[18], 87% of men with early stage prostate cancer [16],
and 70% of patients with advanced incurable cancer
(these patients were not on trials) [17]. The commonality
between these studies is that family was consistently nom-
inated as the most frequent domain. In terms of the index
scores, our average of 69 was higher than that of the group
of advance incurable cancer patients (mean = 58) and the
patients participating in Phase I trials (mean = 61). It was
comparable to the men with early stage prostate cancer
(mean = 71), but the relatively small range of mean scores
among these studies is notable. Construct validity is sup-
ported in that those patients whom one might expect to
have higher QL (i.e. less ill patients), indeed reported
higher QL. That the scores in the current sample were
more comparable to the early stage prostate cancer
patients than the incurable cancer patients may speak to
the hope patients were feeling regarding the potential of
the reovirus treatment.
Patient #1: Cues, Levels and Weights Figure 1
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In terms of the index scores for other illness populations,
patients prior to hip arthroplasty scored 59, after the sur-
gery scores increased to 69 [27], on par with the cancer
patients in this study (mean 69). Another study of hip
replacement patients found scores of 62 prior to surgery,
with improvements to 71 following surgery [28], a similar
improvement pre- to post-surgery. Severely disabled mul-
tiple sclerosis patients scored 61 [29], patients with ALS
had a higher mean index of 76 [30], and cardiac patients
scored a high index of 82 after myocardial infarction or
coronary artery bypass graft surgery and prior to begin-
ning cardiac rehab [31];. Interestingly, only 24% of the
ALS patients nominated health (disease progression) as a
cue. Thus, although the areas of importance varied by
individual in all these studies, the resultant index scores
seem to demonstrate some consistency across similar
populations.
Another indication of the construct validity of the
SEIQoL-DW is its high correlation to global QL scores on
the EORTC QLQ C-30. This speaks to the validity of the
self-generated items, as the sum of the products of their
importance and current status was associated with the
overall global assessment of QL on standardized
domains. Predictably, our patients had a global QL on the
EORTC of 57, much lower than the 77 reported in a large
normative community sample [32]. Scores on all five
functional scales and symptom scores were all also worse
in this population, not surprising considering the extent
of their disease status. However, they did have the same
global QL scores compared to a large sample of patients
with advanced malignancy from 12 institutions in 10
countries (both 57), but scored higher on most of the
other functional scales than this group (Physical function:
64 vs. 60; Role function: 63 vs. 50; Emotional function: 76
vs. 50; Cognitive function: 76 vs. 63; Social Function: 55
vs. 50) [33]. The greatest differences in favor of the
patients in this trial were seen on emotional, cognitive
and role function.
Interestingly, lower global QL scores on the EORTC and
higher depression scores on the BDI were associated with
a shorter time to death in those patients who had already
passed away, an association that has been reported in
other studies [33-35]. In fact, in an international sample
of 411 patients with advanced malignancy, similar to the
Patient #2: Cues, Levels and Weights Figure 2
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current group, the single-item global QL scale remained
independently prognostic of death in a proportional haz-
ards model stratified on diagnostic category, after allow-
ing for performance status and age, and, among solid
tumor patients, metastatic site [33].
Patients who were in terminal care from a large sample
from 12 oncology outpatients departments around the
United States scored an average BSI Global severity index
score of .93. Those who were under symptom control
scored .80, whereas lower scores were seen for patients in
active therapy (.59), adjuvant therapy (.60) or no current
therapy (.65)[36]. Our sample mean of .55 is quite low in
comparison and most comparable to patients in active
therapy. An even larger sample of over 4000 patients of all
disease sites and stages of illness from Johns Hopkins
Oncology Centre reported an average global severity index
very similar to our patients, at .54 [37]. This seems to indi-
cate that our sample is reporting less psychopathology
than would be expected of patients in similar disease
states, but comparable levels to cancer patients in general.
They also scored an average of 11 on the BDI, which indi-
cates mild depressive symptomatology.
The spirituality scores of this group average 118. This is
very similar to a group of lung cancer patients who had a
mean of 120 [20]. Analysis of the individual items
showed that these patients endorsed feeling well sup-
ported by the medical team and quite peaceful and accept-
ing of themselves, and well accepted by others. They
reported not feeling angry at themselves or others, or wor-
ried about life after death. The spirituality scores were cor-
related with the global severity index of the BSI, indicating
that those who felt more spiritually at ease also endorsed
fewer symptoms of psychopathology.
In summary, these patients in a Phase I trial of a promis-
ing novel therapeutic were easily able to complete the
SEIQoL-DW interview as well as a battery of other psycho-
logical questionnaires. They reported feeling excited and
hopeful about the trial, with about two-thirds hoping for
disease regression, and another third optimistically hop-
ing for a cure. However, most acknowledged that
although they hoped for the best they were realistic in
their expectations. The individuality of QL as defined by
each person was reinforced in this group, as many differ-
ent cues were nominated as important and variable
weights were assigned to the same cues. Consistent with
reports from other seriously ill groups, health status
received less focus than other aspects of life, primarily
family relationships and activities. Overall QL on stand-
ardized measures and psychological status was generally
better than other seriously ill patient groups, but
comparable to cancer patients in general. QL and depres-
sion scores were related to time until death in those
patients who had passed away.
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